Last reviewed · How we verify
immunotherapy
immunotherapy is a Non-Standardized Animal Dander Allergenic Extract [EPC] Small molecule drug developed by Shanghai Zhongshan Hospital. It is currently FDA-approved. Also known as: sintilimab, tislelizumab, nivolumab, Camrelizumab.
Immunotherapy is a type of treatment that harnesses or modifies the immune system to prevent, control, or eliminate disease, often by enhancing or restoring immune responses to eradicate cancer. It involves using interventions such as PD-1 and Everolimus to target cancer cells, with clinical trials studying its effectiveness in conditions including colon cancer and lung small cell carcinoma.
At a glance
| Generic name | immunotherapy |
|---|---|
| Also known as | sintilimab, tislelizumab, nivolumab, Camrelizumab, Mainly on PD-1/PD-L1 |
| Sponsor | Shanghai Zhongshan Hospital |
| Drug class | Non-Standardized Animal Dander Allergenic Extract [EPC] |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer (NA)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy (PHASE1)
- Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1, PHASE2)
- Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- immunotherapy CI brief — competitive landscape report
- immunotherapy updates RSS · CI watch RSS
- Shanghai Zhongshan Hospital portfolio CI
Frequently asked questions about immunotherapy
What is immunotherapy?
Who makes immunotherapy?
Is immunotherapy also known as anything else?
What drug class is immunotherapy in?
What development phase is immunotherapy in?
Related
- Drug class: All Non-Standardized Animal Dander Allergenic Extract [EPC] drugs
- Manufacturer: Shanghai Zhongshan Hospital — full pipeline
- Therapeutic area: All drugs in Immunology
- Also known as: sintilimab, tislelizumab, nivolumab, Camrelizumab, Mainly on PD-1/PD-L1
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing